Myelofibrosis is a bone marrow condition that disrupts the body's manufacture of blood cells. Fibrous or scar tissue forms in the bone marrow, resulting in scarring and insufficient blood cell formation. Myelofibrosis is a rare type of chronic leukemia that disrupts blood formation. Myelofibrosis symptoms include severe anemia, tiredness, weakness, and an enlarged spleen. Individuals above the age of 50 are more prone to get the disease. Primary and secondary myelofibrosis are the two types of myelofibrosis. The treatment options are limited, but in 2011, the US Food and Medicine Administration (FDA) approved Jakafi (Ruxolitinib), a Novartis drug that is the only approved product for the treatment of myelofibrosis and acts as a critical line of defense against the condition.
The increased prevalence of myelofibrosis in emerging countries is increasing the demand for various myelofibrosis treatment options. The market is expected to grow because to significant investments in research and development, favorable reimbursement circumstances, and a large pool of patients with myelofibrosis. Lifestyle developments, unmet medical needs of patients, increased prevalence of hereditary illnesses, and an expanding smoking population are all factors leading to market expansion. The market is predicted to increase considerably as medical breakthroughs focus on people suffering from myelofibrosis. Gilead Sciences, for example, created CYT387 or Momelotinib to treat primary myelofibrosis, while Incyte Corporation improved the present medicine, ruxolitinib, to establish a replacement dose method in myelofibrosis patients.
However, the global myelofibrosis therapy market is being held back by a lack of awareness about novel medicines as well as the high treatment costs. North America is likely to dominate the market due to the increasing prevalence of myelofibrosis and favorable reimbursement situations.